Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

SAMER N NAKHLE

Allopathic & Osteopathic Physicians Internal Medicine Endocrinology, Diabetes & Metabolism

NPI
1841281771
CMS profile
356388
Location
LAS VEGAS, NV

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$63,465.01

188 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

By paying entity

PY2024 · entire year · sorted by reported total

Page 4 of 4; records 151–188 of 188 matching records. This page contains 38 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

SAMER N NAKHLE

NPI 1841281771 · CMS profile ID 356388

Allopathic & Osteopathic Physicians / Internal Medicine / Endocrinology, Diabetes & Metabolism

LAS VEGAS, NV

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 4 of 4; records 151–188 of 188 matching records. This page contains 38 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1841281771?year=2024&recipient=provider&page=4#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
SAMER N NAKHLE, NPI 1841281771, CMS profile ID 356388. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 4; records 151–188 of 188 matching records. This page contains 38 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1841281771?year=2024&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). SAMER N NAKHLE, NPI 1841281771, CMS profile ID 356388. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 4; records 151–188 of 188 matching records. This page contains 38 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1841281771?year=2024&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
SAMER N NAKHLE, NPI 1841281771, CMS profile ID 356388, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 4 of 4; records 151–188 of 188 matching records. This page contains 38 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1841281771?year=2024&recipient=provider&page=4#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

188 matching records · $63,465.01 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 188 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 151–188 of 188.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Lilly USA, LLC $17.5702/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135402317 CMS
Lilly USA, LLC $675.0002/20/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135363395 CMS
Lilly USA, LLC $1,800.0002/20/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135384553 CMS
Lilly USA, LLC $14.8302/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135402313 CMS
Lilly USA, LLC $105.3002/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135402315 CMS
Lilly USA, LLC $19.3402/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135372400 CMS
Lilly USA, LLC $1,800.0002/15/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135384551 CMS
Lilly USA, LLC $675.0002/15/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135412947 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $14.4102/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1118176948 CMS
Lilly USA, LLC $14.8402/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135388673 CMS
Lilly USA, LLC $675.0002/12/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135363391 CMS
Lilly USA, LLC $1,800.0002/12/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135412945 CMS
Lilly USA, LLC $17.8502/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135363393 CMS
Lilly USA, LLC $675.0002/08/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135388667 CMS
Lilly USA, LLC $1,800.0002/08/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135412943 CMS
Lilly USA, LLC $3,600.0002/07/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135402309 CMS
Lilly USA, LLC $19.5702/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135402311 CMS
ABBVIE INC. $11.8402/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105096643 CMS
Lilly USA, LLC $1,800.0002/05/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135412939 CMS
Lilly USA, LLC $675.0002/05/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135412941 CMS
Lilly USA, LLC $5.3702/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135342155 CMS
Lilly USA, LLC $25.0002/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135342159 CMS
Lilly USA, LLC $200.8202/01/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135363389 CMS
Lilly USA, LLC $39.7102/01/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135363403 CMS
Lilly USA, LLC $25.0002/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135363405 CMS
Lilly USA, LLC $55.0002/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135372410 CMS
Lilly USA, LLC $60.0002/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135372412 CMS
Lilly USA, LLC $140.0002/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135384565 CMS
Lilly USA, LLC $25.0002/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135388679 CMS
Lilly USA, LLC $35.0002/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135388681 CMS
Lilly USA, LLC $6.4602/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135402333 CMS
Lilly USA, LLC $14.4602/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135412937 CMS
Lilly USA, LLC $230.0502/01/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135412953 CMS
Lilly USA, LLC $299.0002/01/2024 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1155182809 CMS
Lilly USA, LLC $37.5802/01/2024 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1155183667 CMS
Lilly USA, LLC $18.6401/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135388665 CMS
Amgen Inc. $18.5501/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1115958611 CMS
Lilly USA, LLC $900.0001/22/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135372398 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $105,741.62 230
PY2020 $45,700.98 118
PY2021 $48,075.03 112
PY2022 $108,073.90 234
PY2023 $61,859.77 206
PY2024 $63,465.01 188
PY2025 $33,313.77 114

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $3,176,620.85 99
PY2024 Recipient $73,765.20 6
PY2024 Principal investigator $2,678,158.95 361
PY2023 Recipient $2,905.02 4
PY2023 Principal investigator $2,422,525.26 482
PY2022 Recipient $108,874.00 3
PY2022 Principal investigator $1,179,953.77 761
PY2021 Principal investigator $1,638,336.04 1,369
PY2020 Recipient $1,962.53 4
PY2020 Principal investigator $1,001,795.07 638
PY2019 Recipient $6,159.46 26
PY2019 Principal investigator $1,910,652.40 419

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

99 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $5,520.00 12/31/2025 Non-covered Recipient Entity
PALM RESEARCH CENTER INC
A Phase 2/3 multicenter, double blinded, randomized, dose-conversion, active control study examining the efficacy and safety of Armour Thyroid compared to synthetic T4 for the treatment of adults with primary hypothyroidism No dispute reported 06/30/2026 1202532554
Principal investigator 1 Dexcom, Inc. $570.00 12/23/2025 Non-covered Recipient Entity
Palm Research Center
CONTINUOUS GLUCOSE MONITORING SYSTEM USE IN PATIENTS WITH DIABETES A REAL WORLD GLOBAL REGISTRY No dispute reported 06/30/2026 1250961954
Principal investigator 1 Dexcom, Inc. $2,485.00 12/23/2025 Non-covered Recipient Entity
Palm Research Center
EVALUATION OF BASAL INSULIN INITIALIZATION AND TITRATION IN PEOPLE WITH TYPE2 DIABETES WEARING A DEXCOM G6 SENSOR No dispute reported 06/30/2026 1250961960
Principal investigator 1 Boehringer Ingelheim International GmbH $259.74 12/17/2025 Non-covered Recipient Entity
Palm Research Center
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220714282
Principal investigator 1 Boehringer Ingelheim International GmbH $182.50 12/17/2025 Non-covered Recipient Entity
Palm Research Center
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220714284
Principal investigator 1 ABBVIE INC. $1,430.00 12/16/2025 Non-covered Recipient Entity
PALM RESEARCH CENTER INC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202530622
Principal investigator 1 ABBVIE INC. $3,300.00 12/11/2025 Non-covered Recipient Entity
PALM RESEARCH CENTER INC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202530166
Principal investigator 1 ABBVIE INC. $2,700.00 12/10/2025 Non-covered Recipient Entity
PALM RESEARCH CENTER INC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202529878
Principal investigator 1 ABBVIE INC. $11,543.70 12/05/2025 Non-covered Recipient Entity
PALM RESEARCH CENTER INC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202529392
Principal investigator 1 Dexcom, Inc. $960.00 12/02/2025 Non-covered Recipient Entity
Palm Research Center
CONTINUOUS GLUCOSE MONITORING SYSTEM USE IN PATIENTS WITH DIABETES A REAL WORLD GLOBAL REGISTRY No dispute reported 06/30/2026 1250961958
Principal investigator 1 Novo Nordisk AS $2,000.00 11/20/2025 Non-covered Recipient Entity
PALM RESEARCH CENTER
NN8640-4515 No dispute reported 06/30/2026 1214103071
Principal investigator 1 Novo Nordisk AS $3,000.00 11/20/2025 Non-covered Recipient Entity
PALM RESEARCH CENTER
NN8640-4515 No dispute reported 06/30/2026 1214104227
Principal investigator 1 Ionis Pharmaceuticals, Inc. $14,828.00 11/11/2025 Non-covered Recipient Entity
PALM RESEARCH CENTER INC
IS354CS9 No dispute reported 06/30/2026 1246790313
Principal investigator 1 ABBVIE INC. $167,385.72 11/05/2025 Non-covered Recipient Entity
PALM RESEARCH CENTER INC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202523095
Principal investigator 1 Ionis Pharmaceuticals, Inc. $2,964.95 10/29/2025 Non-covered Recipient Entity
PALM RESEARCH CENTER INC
IS354CS15 No dispute reported 06/30/2026 1246789764
Principal investigator 1 Novo Nordisk AS $6,400.00 10/29/2025 Non-covered Recipient Entity
PALM RESEARCH CENTER
NN9535-4801 No dispute reported 06/30/2026 1213706685
Principal investigator 1 Novo Nordisk AS $130.00 10/29/2025 Non-covered Recipient Entity
PALM RESEARCH CENTER
NN9535-4801 No dispute reported 06/30/2026 1213760705
Principal investigator 1 Alexion Pharmaceuticals, Inc. $26,650.00 10/20/2025 Non-covered Recipient Entity
PALM MEDICAL GROUP, LLC
a phase two randomized doubleblinded placebocontrolled dose rangefinding multicenter study to evaluate the efficacy safety and pharmacokinetics of alxn2420 a growth hormone receptor antagonist administered subcutaneously in combination with somatostatin analogs in adult participants with acromegaly No dispute reported 06/30/2026 1185542552
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $360.00 10/09/2025 Non-covered Recipient Entity
PALM RESEARCH CENTER INC
PARADIGHM A NATURAL HISTORY REGISTRY FOR PATIENTS WITH CHRONIC HYPOPARATHYROIDISM No dispute reported 06/30/2026 1223286671
Principal investigator 1 Ionis Pharmaceuticals, Inc. $1,000.00 10/08/2025 Non-covered Recipient Entity
PALM RESEARCH CENTER INC
IS354CS9 No dispute reported 06/30/2026 1246788410
Principal investigator 1 Ionis Pharmaceuticals, Inc. $1,720.00 10/08/2025 Non-covered Recipient Entity
PALM RESEARCH CENTER INC
IS354CS9 No dispute reported 06/30/2026 1246788413
Principal investigator 1 Ionis Pharmaceuticals, Inc. $2,250.00 10/08/2025 Non-covered Recipient Entity
PALM RESEARCH CENTER INC
IS354CS9 No dispute reported 06/30/2026 1246788417
Principal investigator 1 Ionis Pharmaceuticals, Inc. $2,500.00 10/08/2025 Non-covered Recipient Entity
PALM RESEARCH CENTER INC
IS354CS9 No dispute reported 06/30/2026 1246788421
Principal investigator 1 Ionis Pharmaceuticals, Inc. $3,930.80 10/08/2025 Non-covered Recipient Entity
PALM RESEARCH CENTER INC
IS354CS9 No dispute reported 06/30/2026 1246788424
Principal investigator 1 Dexcom, Inc. $2,392.00 10/07/2025 Non-covered Recipient Entity
Palm Research Center
CONTINUOUS GLUCOSE MONITORING SYSTEM USE IN PATIENTS WITH DIABETES A REAL WORLD GLOBAL REGISTRY No dispute reported 06/30/2026 1250961952
Principal investigator 1 Dexcom, Inc. $14,796.00 10/07/2025 Non-covered Recipient Entity
Palm Research Center
EVALUATION OF BASAL INSULIN INITIALIZATION AND TITRATION IN PEOPLE WITH TYPE2 DIABETES WEARING A DEXCOM G6 SENSOR No dispute reported 06/30/2026 1250961956
Principal investigator 1 Ionis Pharmaceuticals, Inc. $1,700.00 10/03/2025 Non-covered Recipient Entity
PALM RESEARCH CENTER INC
IS354CS9 No dispute reported 06/30/2026 1246787935
Principal investigator 1 Ionis Pharmaceuticals, Inc. $2,400.00 10/03/2025 Non-covered Recipient Entity
PALM RESEARCH CENTER INC
IS354CS9 No dispute reported 06/30/2026 1246787939
Principal investigator 1 Novo Nordisk AS $750.00 09/17/2025 Non-covered Recipient Entity
PALM RESEARCH CENTER
NN9535-4801 No dispute reported 06/30/2026 1213767881
Principal investigator 1 Novo Nordisk AS $2,250.00 09/17/2025 Non-covered Recipient Entity
PALM RESEARCH CENTER
NN9535-4801 No dispute reported 06/30/2026 1213786513
Principal investigator 1 Novo Nordisk AS $1,250.00 09/17/2025 Non-covered Recipient Entity
PALM RESEARCH CENTER
NN9535-4801 No dispute reported 06/30/2026 1213846765
Principal investigator 1 Dexcom, Inc. $4,000.00 09/16/2025 Non-covered Recipient Entity
Palm Research Center
Evaluation of the Investigational Dexcom Continuous Monitoring (CGM) Sensor in Adult and Pediatric Subjects No dispute reported 06/30/2026 1250961964
Principal investigator 1 Dexcom, Inc. $4,605.00 09/09/2025 Non-covered Recipient Entity
Palm Research Center
CONTINUOUS GLUCOSE MONITORING SYSTEM USE IN PATIENTS WITH DIABETES A REAL WORLD GLOBAL REGISTRY No dispute reported 06/30/2026 1250961944
Principal investigator 1 Dexcom, Inc. $590.00 09/03/2025 Non-covered Recipient Entity
Palm Research Center
CONTINUOUS GLUCOSE MONITORING SYSTEM USE IN PATIENTS WITH DIABETES A REAL WORLD GLOBAL REGISTRY No dispute reported 06/30/2026 1250961946
Principal investigator 1 Dexcom, Inc. $21,309.00 08/19/2025 Non-covered Recipient Entity
Palm Research Center
CONTINUOUS GLUCOSE MONITORING SYSTEM USE IN PATIENTS WITH DIABETES A REAL WORLD GLOBAL REGISTRY No dispute reported 06/30/2026 1250961942
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $360.00 08/14/2025 Non-covered Recipient Entity
PALM RESEARCH CENTER INC
PARADIGHM A NATURAL HISTORY REGISTRY FOR PATIENTS WITH CHRONIC HYPOPARATHYROIDISM No dispute reported 06/30/2026 1223284235
Principal investigator 1 Globus Medical, Inc. $1,000.00 08/07/2025 Non-covered Recipient Entity
PALM RESEARCH CENTER
A Multi-Center Randomized Controlled Trial to Evaluate Pain and Neurological Function with 10 kHz SCS in Treatment of Painful Diabetic Neuropathy No dispute reported 06/30/2026 1236865543
Principal investigator 1 Ionis Pharmaceuticals, Inc. $4,298.75 08/06/2025 Non-covered Recipient Entity
PALM RESEARCH CENTER INC
IS354CS9 No dispute reported 06/30/2026 1246786065
Principal investigator 1 Ionis Pharmaceuticals, Inc. $2,956.40 08/06/2025 Non-covered Recipient Entity
PALM RESEARCH CENTER INC
IS354CS15 No dispute reported 06/30/2026 1246786258
Principal investigator 1 Ascendis Pharma Endocrinology Inc $7,125.00 07/30/2025 Non-covered Recipient Entity
Palm Research Center Inc
foresiGHt extension No dispute reported 06/30/2026 1233996553
Principal investigator 1 Dexcom, Inc. $9,015.00 07/22/2025 Non-covered Recipient Entity
Palm Research Center
EVALUATION OF BASAL INSULIN INITIALIZATION AND TITRATION IN PEOPLE WITH TYPE2 DIABETES WEARING A DEXCOM G6 SENSOR No dispute reported 06/30/2026 1250961948
Principal investigator 1 Dexcom, Inc. $1,425.00 07/22/2025 Non-covered Recipient Entity
Palm Research Center
CONTINUOUS GLUCOSE MONITORING SYSTEM USE IN PATIENTS WITH DIABETES A REAL WORLD GLOBAL REGISTRY No dispute reported 06/30/2026 1250961950
Principal investigator 1 Novo Nordisk AS $909.35 07/21/2025 Non-covered Recipient Entity
PALM RESEARCH CENTER
NN9535-4801 No dispute reported 06/30/2026 1213810273
Principal investigator 1 ABBVIE INC. $27,789.75 07/02/2025 Non-covered Recipient Entity
PALM RESEARCH CENTER INC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202496121
Principal investigator 1 Eli Lilly and Company $195,620.00 06/16/2025 Non-covered Recipient Entity
PALM RESEARCH CENTER INC
A MASTER PROTOCOL TO INVESTIGATE THE EFFICACY AND SAFETY OF ORFORGLIPRON ONCE DAILY IN PARTICIPANTS WITH HYPERTENSION AND OBESITY OR OVERWEIGHT: RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIALS (ATTAIN-HYPERTENSION). ISAS-GZL1;GZL2 No dispute reported 06/30/2026 1187887766
Principal investigator 1 Dexcom, Inc. $6,014.00 06/10/2025 Non-covered Recipient Entity
Palm Research Center
EVALUATION OF BASAL INSULIN INITIALIZATION AND TITRATION IN PEOPLE WITH TYPE2 DIABETES WEARING A DEXCOM G6 SENSOR No dispute reported 06/30/2026 1250961936
Principal investigator 1 Eli Lilly and Company $506,441.00 06/10/2025 Non-covered Recipient Entity
PALM RESEARCH CENTER INC
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY EVALUATING THE EFFICACY AND SAFETY OF TIRZEPATIDE ONCE WEEKLY COMPARED TO PLACEBO IN ADULT PARTICIPANTS WITH TYPE 1 DIABETES AND OBESITY OR OVERWEIGHT (SURPASS-T1D-1) No dispute reported 06/30/2026 1187890264
Principal investigator 1 ABBVIE INC. $64,681.98 06/03/2025 Non-covered Recipient Entity
PALM RESEARCH CENTER INC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202488565
Principal investigator 1 ABBVIE INC. $850.00 06/03/2025 Non-covered Recipient Entity
PALM RESEARCH CENTER INC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202488567
Principal investigator 1 Dexcom, Inc. $7,136.00 06/03/2025 Non-covered Recipient Entity
Palm Research Center
CONTINUOUS GLUCOSE MONITORING SYSTEM USE IN PATIENTS WITH DIABETES A REAL WORLD GLOBAL REGISTRY No dispute reported 06/30/2026 1250961938
Principal investigator 1 Globus Medical, Inc. $29,128.00 05/29/2025 Non-covered Recipient Entity
PALM RESEARCH CENTER
A Multi-Center Randomized Controlled Trial to Evaluate Pain and Neurological Function with 10 kHz SCS in Treatment of Painful Diabetic Neuropathy No dispute reported 06/30/2026 1236866047
Principal investigator 1 Novo Nordisk AS $2,307.00 05/21/2025 Non-covered Recipient Entity
PALM RESEARCH CENTER
NN9535-4801 No dispute reported 06/30/2026 1213822370
Principal investigator 1 Dexcom, Inc. $13,000.00 05/13/2025 Non-covered Recipient Entity
Palm Research Center
EVALUATION OF BASAL INSULIN INITIALIZATION AND TITRATION IN PEOPLE WITH TYPE2 DIABETES WEARING A DEXCOM G6 SENSOR No dispute reported 06/30/2026 1250961934
Principal investigator 1 ABBVIE INC. $27,885.66 05/07/2025 Non-covered Recipient Entity
PALM RESEARCH CENTER INC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202483351
Principal investigator 1 Globus Medical, Inc. $3,810.00 05/07/2025 Non-covered Recipient Entity
PALM RESEARCH CENTER
A Multi-Center Randomized Controlled Trial to Evaluate Pain and Neurological Function with 10 kHz SCS in Treatment of Painful Diabetic Neuropathy No dispute reported 06/30/2026 1236865881
Principal investigator 1 Eli Lilly and Company $10,501.79 05/01/2025 Non-covered Recipient Entity
PALM RESEARCH CENTER INC
A MASTER PROTOCOL TO INVESTIGATE THE EFFICACY AND SAFETY OF ORFORGLIPRON ONCE DAILY IN PARTICIPANTS WITH HYPERTENSION AND OBESITY OR OVERWEIGHT: RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIALS (ATTAIN-HYPERTENSION). ISAS-GZL1;GZL2 No dispute reported 06/30/2026 1187890268
Principal investigator 1 ABBVIE INC. $7,100.00 04/28/2025 Non-covered Recipient Entity
PALM RESEARCH CENTER INC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202479778
Principal investigator 1 Dexcom, Inc. $5,475.00 04/22/2025 Non-covered Recipient Entity
Palm Research Center
CONTINUOUS GLUCOSE MONITORING SYSTEM USE IN PATIENTS WITH DIABETES A REAL WORLD GLOBAL REGISTRY No dispute reported 06/30/2026 1250961940
Principal investigator 1 Globus Medical, Inc. $11,364.00 04/10/2025 Non-covered Recipient Entity
PALM RESEARCH CENTER
A Multi-Center Randomized Controlled Trial to Evaluate Pain and Neurological Function with 10 kHz SCS in Treatment of Painful Diabetic Neuropathy No dispute reported 06/30/2026 1236866045
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $360.00 04/10/2025 Non-covered Recipient Entity
PALM RESEARCH CENTER INC
PARADIGHM A NATURAL HISTORY REGISTRY FOR PATIENTS WITH CHRONIC HYPOPARATHYROIDISM No dispute reported 06/30/2026 1223277810
Principal investigator 1 ABBVIE INC. $17,911.02 04/03/2025 Non-covered Recipient Entity
PALM RESEARCH CENTER INC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202473109
Principal investigator 1 Novo Nordisk AS $25,794.13 03/31/2025 Non-covered Recipient Entity
PALM RESEARCH CENTER
EX9924-4473 No dispute reported 06/30/2026 1213724781
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,080.00 03/14/2025 Non-covered Recipient Entity
PALM RESEARCH CENTER INC
PARADIGHM A NATURAL HISTORY REGISTRY FOR PATIENTS WITH CHRONIC HYPOPARATHYROIDISM No dispute reported 06/30/2026 1223276359
Principal investigator 1 Dexcom, Inc. $4,090.00 03/11/2025 Non-covered Recipient Entity
Palm Research Center
CONTINUOUS GLUCOSE MONITORING SYSTEM USE IN PATIENTS WITH DIABETES A REAL WORLD GLOBAL REGISTRY No dispute reported 06/30/2026 1250961930
Principal investigator 1 ABBVIE INC. $44,495.34 03/07/2025 Non-covered Recipient Entity
PALM RESEARCH CENTER INC
M21-341 - A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202461881
Principal investigator 1 Dexcom, Inc. $670.00 03/04/2025 Non-covered Recipient Entity
Palm Research Center
CONTINUOUS GLUCOSE MONITORING SYSTEM USE IN PATIENTS WITH DIABETES A REAL WORLD GLOBAL REGISTRY No dispute reported 06/30/2026 1250961926
Principal investigator 1 Eli Lilly and Company $737.50 03/04/2025 Non-covered Recipient Entity
TRIBE CLINICAL RESEARCH LLC
A STUDY OF ORFORGLIPRON FOR THE MAINTENANCE OF BODY WEIGHT REDUCTION IN PARTICIPANTS WHO HAVE OBESITY OR OVERWEIGHT WITH WEIGHT-RELATED COMORBIDITIES (ATTAIN-MAINTAIN) No dispute reported 06/30/2026 1187893620
Principal investigator 1 Amgen Inc. $80,361.55 02/25/2025 Non-covered Recipient Entity
PALM RESEARCH CENTER INC
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight (MARITIME-2) No dispute reported 06/30/2026 1246646269
Principal investigator 1 Amgen Inc. $189,950.07 02/25/2025 Non-covered Recipient Entity
PALM RESEARCH CENTER INC
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight No dispute reported 06/30/2026 1246646278
Principal investigator 1 Dexcom, Inc. $2,501.00 02/25/2025 Non-covered Recipient Entity
Palm Research Center
CONTINUOUS GLUCOSE MONITORING SYSTEM USE IN PATIENTS WITH DIABETES A REAL WORLD GLOBAL REGISTRY No dispute reported 06/30/2026 1250961928
Principal investigator 1 Novo Nordisk AS $6,480.00 02/21/2025 Non-covered Recipient Entity
PALM RESEARCH CENTER
EX9924-4473 No dispute reported 06/30/2026 1213788012
Principal investigator 1 Novo Nordisk AS $4,900.00 02/21/2025 Non-covered Recipient Entity
PALM RESEARCH CENTER
EX9924-4473 No dispute reported 06/30/2026 1213837418
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $360.00 02/13/2025 Non-covered Recipient Entity
PALM RESEARCH CENTER INC
PARADIGHM A NATURAL HISTORY REGISTRY FOR PATIENTS WITH CHRONIC HYPOPARATHYROIDISM No dispute reported 06/30/2026 1223275233
Principal investigator 1 ABBVIE INC. $36,278.82 02/06/2025 Non-covered Recipient Entity
PALM RESEARCH CENTER INC
M21-341 - A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202449639
Principal investigator 1 Eli Lilly and Company $1,103.26 01/31/2025 Non-covered Recipient Entity
PALM RESEARCH CENTER INC
A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND OBESITY OR OVERWEIGHT AT INCREASED CARDIOVASCULAR RISK (ACHIEVE-4) No dispute reported 06/30/2026 1187885252
Principal investigator 1 Eli Lilly and Company $1,887.86 01/31/2025 Non-covered Recipient Entity
PALM RESEARCH CENTER INC
A PHASE 3, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF RETATRUTIDE ONCE WEEKLY COMPARED WITH SEMAGLUTIDE ONCE WEEKLY IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH METFORMIN WITH OR WITHOUT SGLT2 INHIBITOR (TRANSCEND-T2D-2) No dispute reported 06/30/2026 1187887764
Principal investigator 1 Eli Lilly and Company $1,220.10 01/31/2025 Non-covered Recipient Entity
PALM RESEARCH CENTER INC
A RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF LY3437943 ONCE WEEKLY COMPARED TO PLACEBO IN PARTICIPANTS WITH SEVERE OBESITY AND ESTABLISHED CARDIOVASCULAR DISEASE No dispute reported 06/30/2026 1187888314
Principal investigator 1 Globus Medical, Inc. $3,210.00 01/29/2025 Non-covered Recipient Entity
PALM RESEARCH CENTER
A Multi-Center Randomized Controlled Trial to Evaluate Pain and Neurological Function with 10 kHz SCS in Treatment of Painful Diabetic Neuropathy No dispute reported 06/30/2026 1236865713
Principal investigator 1 Shionogi Inc $3,815.70 01/29/2025 Non-covered Recipient Entity
PALM RESEARCH CENTER INC
A Phase 2, Multicenter, Randomized, Double-blind, Dose-ranging, Placebo-controlled Study to Assess the Safety and Efficacy of S-309309 in Obese Adults No dispute reported 06/30/2026 1250719913
Principal investigator 1 Shionogi Inc $3,916.11 01/29/2025 Non-covered Recipient Entity
PALM RESEARCH CENTER INC
A Phase 2, Multicenter, Randomized, Double-blind, Dose-ranging, Placebo-controlled Study to Assess the Safety and Efficacy of S-309309 in Obese Adults No dispute reported 06/30/2026 1250719918
Principal investigator 1 Eli Lilly and Company $26,650.00 01/28/2025 Non-covered Recipient Entity
PALM RESEARCH CENTER INC
A STUDY OF RETATRUTIDE (LY3437943) ON RENAL FUNCTION IN PARTICIPANTS WITH OVERWEIGHT OR OBESITY AND CHRONIC KIDNEY DISEASE WITH OR WITHOUT TYPE 2 DIABETES No dispute reported 06/30/2026 1187887758
Principal investigator 1 Eli Lilly and Company $713.70 01/27/2025 Non-covered Recipient Entity
PALM RESEARCH CENTER INC
THE EFFECT OF TIRZEPATIDE VERSUS DULAGLUTIDE ON MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS WITH TYPE 2 DIABETES (SURPASS CVOT) No dispute reported 06/30/2026 1187887762
Principal investigator 1 Eli Lilly and Company $1,091.82 01/27/2025 Non-covered Recipient Entity
PALM RESEARCH CENTER INC
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF TIRZEPATIDE ON THE REDUCTION OF MORBIDITY AND MORTALITY IN ADULTS WITH OBESITY No dispute reported 06/30/2026 1187888312
Principal investigator 1 Eli Lilly and Company $6,107.38 01/27/2025 Non-covered Recipient Entity
PALM RESEARCH CENTER INC
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH ELEVATED LIPOPROTEIN(A) WHO HAVE ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR ARE AT RISK FOR A FIRST CARDIOVASCULAR EVENT - ACCLAIM-LP(A) No dispute reported 06/30/2026 1187889916
Principal investigator 1 Eli Lilly and Company $3,341.91 01/22/2025 Non-covered Recipient Entity
PALM RESEARCH CENTER INC
A STUDY OF ORFORGLIPRON FOR THE MAINTENANCE OF BODY WEIGHT REDUCTION IN PARTICIPANTS WHO HAVE OBESITY OR OVERWEIGHT WITH WEIGHT-RELATED COMORBIDITIES (ATTAIN-MAINTAIN) No dispute reported 06/30/2026 1187885258
Principal investigator 1 Amgen Inc. $55,336.54 01/21/2025 Non-covered Recipient Entity
PALM RESEARCH CENTER INC
A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Impact of Evolocumab on Major Cardiovascular Events in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke No dispute reported 06/30/2026 1246646264
Principal investigator 1 Eli Lilly and Company $318,608.00 01/21/2025 Non-covered Recipient Entity
PALM RESEARCH CENTER INC
A STUDY OF ORFORGLIPRON FOR THE MAINTENANCE OF BODY WEIGHT REDUCTION IN PARTICIPANTS WHO HAVE OBESITY OR OVERWEIGHT WITH WEIGHT-RELATED COMORBIDITIES (ATTAIN-MAINTAIN) No dispute reported 06/30/2026 1187885250
Principal investigator 1 Eli Lilly and Company $364,983.00 01/21/2025 Non-covered Recipient Entity
PALM RESEARCH CENTER INC
A MASTER PROTOCOL TO INVESTIGATE THE EFFICACY AND SAFETY OF LY3437943 ONCE WEEKLY IN PARTICIPANTS WITHOUT TYPE 2 DIABETES WHO HAVE OBESITY OR OVERWEIGHT: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL (TRIUMPH-1) No dispute reported 06/30/2026 1187887488
Principal investigator 1 Eli Lilly and Company $20,298.00 01/21/2025 Non-covered Recipient Entity
PALM RESEARCH CENTER INC
A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND OBESITY OR OVERWEIGHT AT INCREASED CARDIOVASCULAR RISK (ACHIEVE-4) No dispute reported 06/30/2026 1187888308
Principal investigator 1 Eli Lilly and Company $31,482.00 01/21/2025 Non-covered Recipient Entity
PALM RESEARCH CENTER INC
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF TIRZEPATIDE ON THE REDUCTION OF MORBIDITY AND MORTALITY IN ADULTS WITH OBESITY No dispute reported 06/30/2026 1187889356
Principal investigator 1 Eli Lilly and Company $51,431.00 01/21/2025 Non-covered Recipient Entity
PALM RESEARCH CENTER INC
A RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF LY3437943 ONCE WEEKLY COMPARED TO PLACEBO IN PARTICIPANTS WITH SEVERE OBESITY AND ESTABLISHED CARDIOVASCULAR DISEASE No dispute reported 06/30/2026 1187889750
Principal investigator 1 Eli Lilly and Company $78,484.00 01/21/2025 Non-covered Recipient Entity
PALM RESEARCH CENTER INC
THE EFFECT OF TIRZEPATIDE VERSUS DULAGLUTIDE ON MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS WITH TYPE 2 DIABETES (SURPASS CVOT) No dispute reported 06/30/2026 1187889752
Principal investigator 1 Eli Lilly and Company $97,969.00 01/17/2025 Non-covered Recipient Entity
PALM RESEARCH CENTER INC
A PHASE 3B, RANDOMIZED CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TIRZEPATIDE COMPARED TO SEMAGLUTIDE 2.4 MG IN ADULTS WHO HAVE OBESITY OR OVERWEIGHT WITH WEIGHT-RELATED COMORBIDITIES (SURMOUNT-5) No dispute reported 06/30/2026 1187889754
Principal investigator 1 Eli Lilly and Company $169,965.00 01/17/2025 Non-covered Recipient Entity
PALM RESEARCH CENTER INC
A PHASE 3, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF RETATRUTIDE ONCE WEEKLY COMPARED WITH SEMAGLUTIDE ONCE WEEKLY IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH METFORMIN WITH OR WITHOUT SGLT2 INHIBITOR (TRANSCEND-T2D-2) No dispute reported 06/30/2026 1187889756
Principal investigator 1 Eli Lilly and Company $1,116.75 01/16/2025 Non-covered Recipient Entity
PALM RESEARCH CENTER INC
A MASTER PROTOCOL TO INVESTIGATE THE EFFICACY AND SAFETY OF LY3437943 ONCE WEEKLY IN PARTICIPANTS WITHOUT TYPE 2 DIABETES WHO HAVE OBESITY OR OVERWEIGHT: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL (TRIUMPH-1) No dispute reported 06/30/2026 1187887486
Principal investigator 1 Dexcom, Inc. $3,623.00 01/07/2025 Non-covered Recipient Entity
Palm Research Center
CONTINUOUS GLUCOSE MONITORING SYSTEM USE IN PATIENTS WITH DIABETES A REAL WORLD GLOBAL REGISTRY No dispute reported 06/30/2026 1250961932
Principal investigator 1 Dexcom, Inc. $121.82 01/07/2025 Non-covered Recipient Entity
Palm Research Center
Evaluation of the Investigational Dexcom Continuous Monitoring (CGM) Sensor in Adult and Pediatric Subjects No dispute reported 06/30/2026 1250961962
Principal investigator 1 Eli Lilly and Company $210,945.00 01/07/2025 Non-covered Recipient Entity
PALM RESEARCH CENTER INC
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH ELEVATED LIPOPROTEIN(A) WHO HAVE ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR ARE AT RISK FOR A FIRST CARDIOVASCULAR EVENT - ACCLAIM-LP(A) No dispute reported 06/30/2026 1187887490
Principal investigator 1 Amgen Inc. $36,924.38 01/02/2025 Non-covered Recipient Entity
PALM RESEARCH CENTER INC
A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Olpasiran on Major Cardiovascular Events in Participants With Atherosclerotic Cardiovascular Disease and Elevated Lipoprotein(a) No dispute reported 06/30/2026 1246646260